Followers | 3 |
Posts | 1480 |
Boards Moderated | 0 |
Alias Born | 02/07/2016 |

Saturday, May 17, 2025 9:40:28 AM
I have provided examples (large and small companies including 5 in biotech), commonly known and accepted reasons and recent news related to this topic all showing the positive effects of insider purchases. With the following concrete evidence, I will rest my case and put you on ignore. I think with your last post, you lost the reapect of most readers on this board.
Multiple academic studies show positive correlation between insider purchases and stock returns (see link below):
"At the level of individual firms, Lakonishok and Lee concluded that insider activity can predict stock returns.They found that stocks with extensive insider purchases outperformed those with extensive sales. However, they stated that insider purchases are more informative than insider sales.
"Research showed that long-term positive (negative) excess returns existed afterinsider purchase (sale) transactions. It also showed that multiple trades by different insiders in the same direction led to higher excess returns."
https://www.2iqresearch.com/blog/profiting-from-insider-transactions-a-review-of-the-academic-research
Recent HALO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2025 09:33:05 PM
- Halozyme to Participate at Upcoming Investor Conferences • PR Newswire (US) • 05/28/2025 08:05:00 PM
- Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications • PR Newswire (US) • 05/28/2025 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2025 08:08:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2025 08:06:31 PM
- HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS • PR Newswire (US) • 05/06/2025 08:01:00 PM
- Halozyme to Participate in the BofA Securities 2025 Healthcare Conference • PR Newswire (US) • 05/05/2025 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2025 08:11:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2025 08:08:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/02/2025 08:07:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2025 08:06:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2025 08:04:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2025 08:02:32 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/28/2025 09:18:36 PM
- Halozyme to Report First Quarter 2025 Financial and Operating Results • PR Newswire (US) • 04/28/2025 12:30:00 PM
- Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) • PR Newswire (US) • 04/28/2025 11:30:00 AM
- Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation • PR Newswire (US) • 04/24/2025 12:30:00 PM
- Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy • PR Newswire (US) • 04/10/2025 10:15:00 PM
- European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility • PR Newswire (US) • 04/09/2025 12:45:00 PM
- European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer • PR Newswire (US) • 04/07/2025 01:29:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2025 10:32:16 PM
- Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications • PR Newswire (US) • 03/31/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/21/2025 08:03:19 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/18/2025 08:17:06 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/18/2025 08:14:31 PM
VAYK to Acquire Up to $9 million in Time-share Vacation Properties Through Non-Cash Deals • VAYK • Jun 11, 2025 9:45 AM
ECGI Holdings Invests in AI-Powered Fantasy Sports Startup Payday Fantasy • ECGI • Jun 10, 2025 8:30 AM
Avant Technologies Signs Letter of Intent for a Business Combination • AVAI • Jun 10, 2025 8:00 AM
NEXT10, Inc. Announces Acquisition of Torreon Group, Inc. • NXTN • Jun 9, 2025 8:42 AM
Maybacks Global Entertainment, LLC and Plex Sign Global Licensing and Distribution Agreement • AHRO • Jun 6, 2025 8:30 AM
Omega Laboratories Delivers Marijuana Breath Test Validation Packet to Cannabix Technologies Inc. - Completing Major Milestone under Strategic Partnership • BLOZF • Jun 5, 2025 8:54 AM